Stay updated on CABozantinib in NSCLC MET Clinical Trial
Sign up to get notified when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.

Latest updates to the CABozantinib in NSCLC MET Clinical Trial page
- Check2 days agoChange DetectedPadova, PD, Italy 35128 has been added and Padua, PD, Italy 35128 removed from the locations list.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check59 days agoChange DetectedAdded Revision: v3.4.2; removed the government funding notice and the prior Revision: v3.4.1.SummaryDifference0.3%

- Check66 days agoChange DetectedThe page now displays a site-wide funding status notice and has a version update from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check74 days agoChange DetectedAdded a Show glossary toggle and updated metadata labels: 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', along with a new 'Revision: v3.4.0' tag. The previous labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were replaced.SummaryDifference0.2%

Stay in the know with updates to CABozantinib in NSCLC MET Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.